Development of a treatment algorithm for kinase inhibitor therapy in CML.

点击翻译按钮获取中文摘要

Chronic myeloid leukaemia has become a highly treatable condition since targeted therapy became available. There are now 3 highly effective drugs available, imatinib, nilotinib and dasatinib. We are developing drug sensitivity assays that can be used to predict response to these 3 drugs. We propose that these assays could be used to individualise therapy to ensure that the optimal drug can be provided for each patient from diagnosis to provide a cost-effective customized approach to therapy.